Wendell Wierenga, Ph.D., has served as a member of our Board of Directors since February 2011.
From June 2011 to January 2014, Dr. Wierenga served as Executive Vice President, Research and Development at Santarus, Inc. From 2006 to 2011, he served as Executive Vice President, Research and Development at Ambit Biosciences Corporation. From 2003 to 2006, he served as Executive Vice President of Research and Development at Neurocrine Biosciences, Inc. From 2000 to 2003, Dr. Wierenga served as Chief Executive Officer of Syrrx, Inc. (now part of Takeda Pharmaceutical Company). From 1990 to 2000, he was Senior Vice President of Worldwide Pharmaceutical Sciences, Technologies and Development at Parke-Davis/Warner Lambert (now Pfizer, Inc.). Prior to that, Dr. Wierenga spent 16 years at Upjohn Pharmaceuticals in research and drug discovery roles, most recently as Executive Director of Discovery Research.
Dr. Wierenga has served on the Board of Directors of several companies including XenoPort, Inc. from 2001 until its acquisition by Arbor Pharmaceuticals in 2017, Ocera Therapeutics, Inc. from December 2013 until its acquisition by Mallinckrodt in 2018, Apricus Biosciences, Inc. from 2013 until its acquisition by Seelos in 2018, Concert Pharmaceuticals, Inc. from March 2014 through 2020, Anacor Pharmaceuticals, Inc. from September 2014 until its acquisition by Pfizer in 2017, and Onyx Pharmaceuticals, Inc. from 1996 until its acquisition by Amgen in 2013.
Dr. Wierenga currently chairs the Board of Crinetics Pharmaceuticals since 2015 and has been serving on the Board of Directors of Dermata Therapeutics since 2016.
Dr. Wierenga holds a B.A. from Hope College and a Ph.D. in Chemistry from Stanford University.
What is Wendell Wierenga's net worth?
The estimated net worth of Wendell Wierenga is at least $2.06 million as of October 27th, 2025. Wierenga owns 32,444 shares of Cytokinetics stock worth more than $2,055,327 as of December 15th. This net worth approximation does not reflect any other investments that Wierenga may own. Learn More about Wendell Wierenga's net worth.
How do I contact Wendell Wierenga?
Has Wendell Wierenga been buying or selling shares of Cytokinetics?
In the last ninety days, Wendell Wierenga has sold $256,725.00 of Cytokinetics stock. Most recently, Wendell Wierenga sold 4,375 shares of the business's stock in a transaction on Monday, October 27th. The shares were sold at an average price of $58.68, for a transaction totalling $256,725.00. Following the completion of the sale, the director now directly owns 32,444 shares of the company's stock, valued at $1,903,813.92. Learn More on Wendell Wierenga's trading history.
Who are Cytokinetics' active insiders?
Cytokinetics' insider roster includes Muna Bhanji (Director), Robert Blum (President and Chief Executive Officer), Andrew Callos (EVP), Santo Costa (Director), David Cragg (Insider), L. Gage (Director), Robert Harrington (Director), John Henderson (Director), Ching Jaw (CFO), Edward Kaye (Director), Fady Malik (EVP), B. Parshall (Director), Mark Schlossberg (SVP), Sandford Smith (Director), Wendall Wierenga (Director), Wendell Wierenga (Director), and Robert Wong (CAO). Learn More on Cytokinetics' active insiders.
Are insiders buying or selling shares of Cytokinetics?
During the last year, insiders at the biopharmaceutical company sold shares 52 times. They sold a total of 305,903 shares worth more than $15,790,304.00. The most recent insider tranaction occured on December, 8th when EVP Andrew Callos sold 1,042 shares worth more than $68,730.32. Insiders at Cytokinetics own 3.4% of the company.
Learn More about insider trades at Cytokinetics. Information on this page was last updated on 12/8/2025.
